The PRISMA study flowchart. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for FEV1/FVC. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for clinical efficacy. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for FEV1. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

The excluded and included studies were listed. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for PaCO₂. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

Forest plot for PaO₂. حسب Xuqin Du (8803772)

"…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …"

The timeline of the experiment. حسب Shadi Nazarizadeh (20108029)

"…EEG power in the HINS group decreased significantly compared to other experimental groups (p<0.05). …"

S1 Raw data - حسب Shadi Nazarizadeh (20108029)

"…EEG power in the HINS group decreased significantly compared to other experimental groups (p<0.05). …"

S1 Graphical abstract - حسب Shadi Nazarizadeh (20108029)

"…EEG power in the HINS group decreased significantly compared to other experimental groups (p<0.05). …"

Bacterium-Phage Symbiosis Facilitates the Enrichment of Bacterial Pathogens and Antibiotic-Resistant Bacteria in the Plastisphere حسب Rong Xia (30438)

"…The plastisphere phage community exhibited decreased diversity and virulent proportion compared to those found in environments. …"

DPOAE differences (in dB SPL), post-scan minus pre-scan, as a function of the F2 frequency. حسب Eddy Fortier (20577301)

DPOAE differences (in dB SPL), delayed observation minus baseline, as a function of the F2 frequency. حسب Eddy Fortier (20577301)

Molecular docking results of CXCR4-modulator 1 with CXCR4 protein using PyRx software. حسب Bonoshree Sarkar (20469331)

RE-AIM indicators. حسب Gadapani Barsha Pathak (20700684)

"…The secondary outcome includes a robust estimation of burden, timing, and risk factors of stillbirths across all study sites. …"

Logic model based on ERIC-CFIR. حسب Gadapani Barsha Pathak (20700684)

"…The secondary outcome includes a robust estimation of burden, timing, and risk factors of stillbirths across all study sites. …"

Flow chart of the study participants. حسب Milton W. Musaba (8431944)

"…</p><p>Results</p><p>Bedside resuscitation increased significantly in the post-implementation period (9.3% versus 45.3%, <i>p</i> < 0.001 while early cord clamping decreased (26.7% versus 12.0%, <i>p</i> = 0.042). …"

Suggested modifications for the BabySaver. حسب Milton W. Musaba (8431944)

"…</p><p>Results</p><p>Bedside resuscitation increased significantly in the post-implementation period (9.3% versus 45.3%, <i>p</i> < 0.001 while early cord clamping decreased (26.7% versus 12.0%, <i>p</i> = 0.042). …"

Structural analysis of wild type and mutated variants of CXCR4. حسب Bonoshree Sarkar (20469331)

Using Penalized Synthetic Controls on Truncated Data: A Case Study on Effect of Marijuana Legalization on Direct Payments to Physicians by Opioid Manufacturers حسب Bikram Karmakar (6494186)

"…Our analysis finds a significant decrease in direct payments from opioid manufacturers to pain medicine physicians as an effect of MML passage. …"